Research Library › Peptide Fragments
LL-37 is a naturally occurring 37-amino-acid antimicrobial peptide and the only cathelicidin encoded in the human genome; it is cleaved from a larger precursor protein, hCAP18. It was first reported in 1995 as FALL-39 by B. Agerberth, G.H. Gudmundsson, H.G. Boman and colleagues, and the mature LL-37 form was described in 1996. As of 22 Oct 2026 no approval of LL-37 by any regulator has been found, and it is not FDA-approved.
Key facts
| Type | Natural 37-amino-acid antimicrobial peptide (human cathelicidin) |
|---|---|
| Derived from | Precursor protein hCAP18, produced by white blood cells |
| Other names | Cathelicidin LL-37, FALL-39 (predicted precursor peptide), ropocamptide (drug candidate) |
| First described | 1995 as FALL-39; mature LL-37 described 1996 |
| Discovered by | B. Agerberth, G.H. Gudmundsson, H.G. Boman and colleagues; gene also cloned independently by J.W. Larrick's team |
| Natural role | Part of innate host defense against bacteria |
| Regulatory status (Oct 2026) | Not FDA-approved; removed from FDA Category 2 in April 2026 pending advisory review planned before end of February 2027 |
Who discovered it
LL-37 was first reported in 1995 by B. Agerberth and G.H. Gudmundsson, working with H.G. Boman and colleagues [1]. A team led by J.W. Larrick independently cloned the same gene, with results reported in 1996 [2]. Also in 1996, Gudmundsson, Agerberth and co-workers described how the precursor is processed into the mature peptide in white blood cells [3].
The Swedish company Promore Pharma later developed a drug candidate based on LL-37, named ropocamptide [4].
Structure and natural role
LL-37 is cut from a larger protein called hCAP18, which is produced by granulocytes, a class of white blood cells. The peptide was first predicted from the gene as a 39-amino-acid sequence, FALL-39. The mature peptide turned out to be 37 amino acids long and to begin with two leucines, which gives LL-37 its name [1, 3].
It belongs to the cathelicidin family of antimicrobial peptides, part of the innate immune system’s defense against bacteria. Laboratory studies have also reported interactions with skin cells and fibroblasts [3, 4].
Why it was studied
The original search was for a human counterpart to PR-39, an antibacterial peptide found in pig intestine. At the time, defensins were the only known human peptide antibiotics [1]. The 1996 gene study concluded that FALL39 is the only member of the cathelin gene family in the human genome [3].
Promore Pharma investigated ropocamptide as a topical gel in a research program on venous leg ulcers. Its phase IIb trial, HEAL LL-37, enrolled 144 patients in Sweden and Poland; the company reported no statistically significant difference among the three study groups in the overall analysis [4, 5]. Promore later merged into PMD Device Solutions at the end of 2023, and bankruptcy notices followed in December 2024 and January 2025 [6, 7].
Research timeline
- 1995: FALL-39 reported, expressed in bone marrow and testis [1]
- 1996: Processing to mature LL-37 in granulocytes described [3]
- 2020: Promore reports phase IIb HEAL LL-37 results [4]
- 2023: Promore merges into PMD Device Solutions [6]
- April 2026: FDA removes LL-37 from its Category 2 compounding list [8]
Regulatory status as of October 2026
No regulatory approval of LL-37 or ropocamptide has been found in any country, and it is not FDA-approved. The FDA’s list of bulk substances that may present significant safety risks in compounding cited animal findings related to male reproduction and possible tumor-promoting effects [9].
In April 2026 the FDA removed LL-37 from that Category 2 list, pending a review by its Pharmacy Compounding Advisory Committee planned before the end of February 2027 [8]. On 14 Oct 2026 an FDA interim access policy covering certain peptides was sent to the White House for review; its contents were not public [10].
LL-37 is not named on the 2026 WADA Prohibited List; section S0 covers substances with no approval for human therapeutic use [11].
Available from Kalibra Labs
Supplied as a lyophilized research material with a Certificate of Analysis matched to each lot number.
Frequently asked questions
What is LL-37?
LL-37 is a 37-amino-acid antimicrobial peptide, the only cathelicidin made by humans, cleaved from the precursor protein hCAP18 [1, 3].
Who discovered LL-37?
B. Agerberth, G.H. Gudmundsson, H.G. Boman and colleagues first reported it as FALL-39 in 1995, and described the mature LL-37 form in 1996 [1, 3].
Why is it called LL-37?
The mature peptide is 37 amino acids long and begins with two leucine (L) residues [3].
Is LL-37 FDA approved?
No. As of 22 Oct 2026 LL-37 is not FDA-approved, and an FDA advisory review of its compounding status is planned before the end of February 2027 [8].
Sources
- Agerberth B, Gunne H, Odeberg J, Kogner P, Boman HG, Gudmundsson GH. FALL-39, a putative human peptide antibiotic, is cysteine-free and expressed in bone marrow and testis. Proc Natl Acad Sci USA. 1995;92(1):195–199. PMID 7529412. Link
- INSERM DSIMB RESPIRE database. Cathelicidin antimicrobial peptide (CAMP): discovery and naming. Link
- Gudmundsson GH, Agerberth B, Odeberg J, Bergman T, Olsson B, Salcedo R. The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. Eur J Biochem. 1996;238(2):325–332. PMID 8681941. Link
- Promore Pharma AB. Press release on the phase IIb HEAL LL-37 study of ropocamptide. 19 Nov 2020. Link
- Promore Pharma AB. Interim report January–September 2020. Link
- BioSpace. PMD Device Solutions: new name and ticker symbol (formerly Promore Pharma), Jan 2024. Link
- MFN. Promore Pharma / PMD Device Solutions press releases, incl. bankruptcy notices 22 Dec 2024 and 14 Jan 2025. Link
- Faviero GF, Asebey EJ (Frier Levitt). FDA to remove 12 popular peptides from the Category 2 “do not compound” list. 16 Apr 2026. Link
- U.S. FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (KPV and cathelicidin LL-37 entries). Content current as of 22 Apr 2026. Link
- Office of Information and Regulatory Affairs (reginfo.gov). HHS/FDA, Interim Access Policy for Compounding Using Certain Peptides, RIN 0910-ZD94: received 14 Oct 2026, pending review. Link
- World Anti-Doping Agency. 2026 Prohibited List. Link
Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.
For Research Use Only. Kalibra Labs supplies this compound as a lyophilized research material for in-vitro laboratory use. It is not for human or veterinary use and not for use in diagnostic or therapeutic procedures. This page is a scientific and historical reference; it is not medical advice and makes no claim about use in people or animals.
